Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250326 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT02250326 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 240 participants.
The verdict
NCT02250326, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab, and nab-paclitaxel monotherapy in subjects with advanced non-small cell lung cancer (NSCLC).
Interventions
- DRUG CC-486
- DRUG nab-paclitaxel IV
- DRUG Duravalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2015-01-07 |
| Est. Completion | 2023-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02250326
The ClinicalTrials.gov registry entry for NCT02250326 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CC-486 is the first listed.
NCT02250326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02250326 about?
NCT02250326 is a clinical study titled "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer". This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab, and nab-paclitaxel monotherapy in subjects with advanced non-small cell...
What is the current status of trial NCT02250326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2015-01-07. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT02250326?
The interventions under investigation include: CC-486 (DRUG), nab-paclitaxel IV (DRUG), Duravalumab (DRUG).
Who is sponsoring clinical trial NCT02250326?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.